Resistance to antimicrobial chemotherapy: a prescription for research and action.

The growing problem of resistance to antimicrobial chemotherapy was discussed by participants at the February 1995 workshop at Emory University on population biology, evolution, and control of infectious diseases. They discussed the nature and source of this problem and identified areas of research in which information is lacking for the development of programs to control of the emergence and spread of resistant bacteria. Particular attention was given to theoretical (mathematical modeling) and empirical studies of the within and between-host population biology (epidemiology) and the evolution of microbial resistance to chemotherapeutic agents. Suggestions were made about the kinds of models and data needed, and the procedures that could be employed to stem the ascent and dissemination of resistant bacteria. This article summarizes the observations and recommendations made at the 1995 meeting and in the correspondence between participants that followed. It concludes with an update on the theoretical and empirical research on the between- and within-host population biology and evolution of resistance to antimicrobial chemotherapy most of which has been done since that meeting.

[1]  C. L. Moberg.  Special Article: René Dubos: A Harbinger of Microbial Resistance to Antibiotics , 1996 .

[2]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[3]  C. L. Moberg.  René Dubos, a Harbinger of Microbial Resistance to Antibiotics , 2015, Microbial drug resistance.

[4]  J. Cohen.  Vaccines get a new twist. , 1994, Science.

[5]  M A Nowak,et al.  Pre-existence and emergence of drug resistance in HIV-1 infection. , 1997, Proceedings. Biological sciences.

[6]  M A Nowak,et al.  Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Hawkins,et al.  Discovery of antibodies. , 1992, BMJ.

[8]  P Huovinen,et al.  The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. , 1997, The New England journal of medicine.

[9]  M Kakehashi,et al.  The transmission dynamics of antibiotic–resistant bacteria: the relationship between resistance in commensal organisms and antibiotic consumption , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[10]  R. O'brien,et al.  USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. , 1990, Annals of internal medicine.

[11]  H. Neu,et al.  The Crisis in Antibiotic Resistance , 1992, Science.

[12]  F. M. Stewart,et al.  The population genetics of antibiotic resistance. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M A Nowak,et al.  Human immunodeficiency virus drug therapy and virus load , 1997, Journal of virology.

[14]  R. Danner,et al.  Anti-endotoxin monoclonal antibodies. , 1992, The New England journal of medicine.

[15]  S. Blower,et al.  Control Strategies for Tuberculosis Epidemics: New Models for Old Problems , 1996, Science.

[16]  T. Mckeown.  The Role of Medicine , 1979 .

[17]  A. Tomasz,et al.  Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop. , 1994, The New England journal of medicine.

[18]  M A Nowak,et al.  Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. , 1997, Journal of theoretical biology.

[19]  B. Levin,et al.  The population dynamics of antimicrobial chemotherapy , 1997, Antimicrobial agents and chemotherapy.

[20]  D. Burke.  Vaccine therapy for HIV: a historical review of the treatment of infectious diseases by active specific immunization with microbe-derived antigens. , 1993, Vaccine.

[21]  B. Levin,et al.  Adaptation to the fitness costs of antibiotic resistance in Escherichia coli , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[22]  S. Levy,et al.  High frequency of antimicrobial resistance in human fecal flora , 1988, Antimicrobial Agents and Chemotherapy.

[23]  H. Smith,et al.  Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. , 1983, Journal of general microbiology.

[24]  D. Gordon,et al.  Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. , 1985, The American journal of gastroenterology.

[25]  Christopher J. L. Murray,et al.  Tuberculosis: Commentary on a Reemergent Killer , 1992, Science.

[26]  S. Levy.  Balancing the drug-resistance equation. , 1994, Trends in microbiology.

[27]  S. Paulous,et al.  Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. , 1996, The Journal of general virology.

[28]  M A Nowak,et al.  Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Dubos,et al.  THE MULTIPLICATION OF BACTERIOPHAGE IN VIVO AND ITS PROTECTIVE EFFECT AGAINST AN EXPERIMENTAL INFECTION WITH SHIGELLA DYSENTERIAE , 1943, The Journal of experimental medicine.

[30]  S. Schrag,et al.  Reducing antibiotic resistance , 1996, Nature.

[31]  E Massad,et al.  Modeling and simulating the evolution of resistance against antibiotics. , 1993, International journal of bio-medical computing.

[32]  P Huovinen,et al.  Development of beta-lactamase-mediated resistance to penicillin in middle-ear isolates of Moraxella catarrhalis in Finnish children, 1978-1993. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Julian Adams,et al.  COEVOLUTION IN BACTERIAL‐PLASMID POPULATIONS , 1991, Evolution; international journal of organic evolution.

[34]  J. Hughes,et al.  Trends in antimicrobial drug prescribing among office-based physicians in the United States. , 1995, JAMA.

[35]  H. Smith,et al.  Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. , 1982, Journal of general microbiology.

[36]  M. Kimura,et al.  An introduction to population genetics theory , 1971 .

[37]  J. Mcgowan,et al.  Antimicrobial resistance in hospital organisms and its relation to antibiotic use. , 1983, Reviews of infectious diseases.

[38]  K. M. Shaw,et al.  The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. , 1987, Journal of general microbiology.

[39]  E. Zell,et al.  Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. , 1993, JAMA.

[40]  J. E. Bouma,et al.  Evolution of a bacteria/plasmid association , 1988, Nature.

[41]  S. Lindsay,et al.  The effect of insecticide-treated bed nets on mortality of Gambian children , 1991, The Lancet.

[42]  J. Mcgowan,et al.  Control of antimicrobial resistance in the health care system. , 1997, Infectious disease clinics of North America.

[43]  M. Pfaller,et al.  The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. , 1995, American journal of infection control.

[44]  S Bonhoeffer,et al.  Evaluating treatment protocols to prevent antibiotic resistance. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Mitchell L. Cohen.  Epidemiology of Drug Resistance: Implications for a Post—Antimicrobial Era , 1992, Science.

[46]  R. Nelson,et al.  Recolonization Therapy with Nonadhesive Escherichia coli for Treatment of Inflammatory Bowel Disease , 1994, Annals of the New York Academy of Sciences.

[47]  M. Finland.  Adventures with antibacterial drugs , 1972, Clinical pharmacology and therapeutics.

[48]  A. Tomasz,et al.  Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary. , 1991, The Journal of infectious diseases.

[49]  L. Mcfarland,et al.  Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters , 1987, Antimicrobial Agents and Chemotherapy.

[50]  S. Frost,et al.  Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection , 1994, AIDS.

[51]  F. Tenover,et al.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. , 1997, The Journal of antimicrobial chemotherapy.